REPLIMUNE GROUP, INC. (REPL) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-279.06M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.94× | Operating cash flow / net income. Period ending 2026-06-30. $-279.06M ÷ $-296.97M ≈ 0.94× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -279.06M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -296.97M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-279.06M | (m) | (m) | (m) | (m) | $-296.97M | (m) | (m) | (m) | 0.94× |
| 2026-03-31 | (m) | (m) | $-280.34M | (m) | (m) | (m) | (m) | $-313.94M | (m) | (m) | (m) | 0.89× |
| 2025-12-31 | (m) | (m) | $-277.91M | (m) | (m) | (m) | (m) | $-314.85M | (m) | (m) | (m) | 0.88× |
| 2025-09-30 | (m) | (m) | $-262.67M | (m) | (m) | (m) | (m) | $-310.26M | (m) | (m) | (m) | 0.85× |
| 2025-06-30 | (m) | (m) | $-220.10M | (m) | (m) | (m) | (m) | $-280.22M | (m) | (m) | (m) | 0.79× |
| 2025-03-31 | (m) | (m) | $-192.25M | (m) | (m) | (m) | (m) | $-247.30M | (m) | (m) | (m) | 0.78× |
| 2024-12-31 | (m) | (m) | $-184.69M | (m) | (m) | (m) | (m) | $-228.24M | (m) | (m) | (m) | 0.81× |
| 2024-09-30 | (m) | (m) | $-181.09M | (m) | (m) | (m) | (m) | $-213.02M | (m) | (m) | (m) | 0.85× |
| 2024-06-30 | (m) | (m) | $-186.05M | (m) | (m) | (m) | (m) | $-220.01M | (m) | (m) | (m) | 0.85× |
| 2024-03-31 | (m) | (m) | $-185.47M | (m) | (m) | (m) | (m) | $-215.79M | (m) | (m) | (m) | 0.86× |
| 2023-12-31 | (m) | (m) | $-172.10M | (m) | (m) | (m) | (m) | $-209.96M | (m) | (m) | (m) | 0.82× |
| 2023-09-30 | (m) | (m) | $-153.56M | (m) | (m) | (m) | (m) | $-198.53M | (m) | (m) | (m) | 0.77× |
| 2023-06-30 | $-144.83M | (m) | $-143.18M | $1.65M | (m) | (m) | (m) | $-181.59M | (m) | (m) | (m) | 0.79× |
| 2023-03-31 | $-130.32M | (m) | $-128.05M | $2.27M | (m) | (m) | (m) | $-174.28M | (m) | (m) | (m) | 0.73× |
| 2022-12-31 | $-120.98M | (m) | $-117.81M | $3.17M | (m) | (m) | (m) | $-156.74M | (m) | (m) | (m) | 0.75× |
| 2022-09-30 | $-110.65M | (m) | $-107.57M | $3.08M | (m) | (m) | (m) | $-146.72M | (m) | (m) | (m) | 0.73× |
| 2022-06-30 | $-100.43M | (m) | $-97.32M | $3.11M | (m) | (m) | (m) | $-132.98M | (m) | (m) | (m) | 0.73× |
| 2022-03-31 | $-84.52M | (m) | $-82.18M | $2.34M | (m) | (m) | (m) | $-118.04M | (m) | (m) | (m) | 0.70× |
| 2021-12-31 | $-77.70M | (m) | $-75.75M | $1.95M | (m) | (m) | (m) | $-107.84M | (m) | (m) | (m) | 0.70× |
| 2021-09-30 | $-72.50M | (m) | $-70.39M | $2.10M | (m) | (m) | (m) | $-99.95M | (m) | (m) | (m) | 0.70× |
| 2021-06-30 | $-66.36M | (m) | $-64.61M | $1.75M | (m) | (m) | (m) | $-90.69M | (m) | (m) | (m) | 0.71× |
| 2021-03-31 | $-63.78M | (m) | $-61.39M | $2.39M | (m) | (m) | (m) | $-80.87M | (m) | (m) | (m) | 0.76× |
| 2020-12-31 | $-59.48M | (m) | $-56.52M | $2.96M | (m) | (m) | (m) | $-75.16M | (m) | (m) | (m) | 0.75× |
| 2020-09-30 | $-65.67M | (m) | $-59.27M | $6.40M | (m) | (m) | (m) | $-69.57M | (m) | (m) | (m) | 0.85× |
| 2020-06-30 | $-69.17M | (m) | $-62.06M | $7.11M | (m) | (m) | (m) | $-60.61M | (m) | (m) | (m) | 1.02× |
| 2020-03-31 | $-67.09M | (m) | $-60.55M | $6.54M | (m) | (m) | (m) | $-52.63M | (m) | (m) | (m) | 1.15× |
| 2019-12-31 | $-62.37M | (m) | $-55.32M | $7.05M | (m) | (m) | (m) | $-43.49M | (m) | (m) | (m) | 1.27× |
| 2019-09-30 | $-49.32M | (m) | $-45.69M | $3.63M | (m) | (m) | (m) | $-34.98M | (m) | (m) | (m) | 1.31× |
| 2019-06-30 | $-34.95M | (m) | $-32.10M | $2.85M | (m) | (m) | (m) | $-30.30M | (m) | (m) | (m) | 1.06× |
| 2019-03-31 | $-27.98M | (m) | $-25.38M | $2.60M | (m) | (m) | (m) | $-30.83M | (m) | (m) | (m) | 0.82× |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $-16.15M | (m) | $-16.01M | $136.00K | (m) | (m) | (m) | $-19.70M | (m) | (m) | (m) | 0.81× |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $-7.32M | (m) | $-7.08M | $238.00K | (m) | (m) | (m) | $-7.70M | (m) | (m) | (m) | 0.92× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |